- Home
- ATOS vs COLA Comparison
ATOS vs COLA Comparison
Compare ATOS & COLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- COLA
- Stock Information
- Founded
- ATOS 2009
- COLA 2024
- Country
- ATOS United States
- COLA Singapore
- Employees
- ATOS N/A
- COLA N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- COLA
- Sector
- ATOS Health Care
- COLA
- Exchange
- ATOS Nasdaq
- COLA NYSE
- Market Cap
- ATOS 96.8M
- COLA 79.8M
- IPO Year
- ATOS 2012
- COLA 2025
- Fundamental
- Price
- ATOS $0.89
- COLA $10.05
- Analyst Decision
- ATOS Strong Buy
- COLA
- Analyst Count
- ATOS 3
- COLA 0
- Target Price
- ATOS $7.13
- COLA N/A
- AVG Volume (30 Days)
- ATOS 611.2K
- COLA 49.2K
- Earning Date
- ATOS 05-13-2025
- COLA 01-01-0001
- Dividend Yield
- ATOS N/A
- COLA N/A
- EPS Growth
- ATOS N/A
- COLA N/A
- EPS
- ATOS N/A
- COLA N/A
- Revenue
- ATOS N/A
- COLA N/A
- Revenue This Year
- ATOS N/A
- COLA N/A
- Revenue Next Year
- ATOS N/A
- COLA N/A
- P/E Ratio
- ATOS N/A
- COLA N/A
- Revenue Growth
- ATOS N/A
- COLA N/A
- 52 Week Low
- ATOS $0.55
- COLA $9.95
- 52 Week High
- ATOS $1.74
- COLA $10.10
- Technical
- Relative Strength Index (RSI)
- ATOS 64.44
- COLA N/A
- Support Level
- ATOS $0.78
- COLA N/A
- Resistance Level
- ATOS $0.92
- COLA N/A
- Average True Range (ATR)
- ATOS 0.06
- COLA 0.00
- MACD
- ATOS 0.01
- COLA 0.00
- Stochastic Oscillator
- ATOS 81.82
- COLA 0.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About COLA COLUMBUS ACQUISITION CORP
Columbus Acquisition Corp is a blank check company.